Covid-19 Vaccine: is it a Deed of Daring for the Heart in the House of ADE?

Salvatore Patanè


Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) represents an ongoing global challenge and it is placing considerable strain on healthcare and economic systems. Covid-19 often presents as an acute cardiac injury cardiomyopathy, in the absence of obstructive coronary artery disease denominated ACovCS. Research has called attention to several mechanisms related to cardiovascular involvement and lately, growing evidences link heart dysfunction to an intricate cross talk between Toll-Like Receptor and Notch signaling pathways. Up to date, no proven effective therapies currently exist and worldwide there is a great expectancy of a vaccine. In this context perplexing concern regards possible antibody dependent enhancement (ADE) of SARS-CoV-2 and the potential role of Th17 responses on eosinophilic immunopathology. Until now,Covid-19 vaccine would seem a deed of daring for the heart in the house of ADE. The hope is that a safe and protective vaccine could represent the most effective strategy also for prevention of future outbreaks of this virus and that in addition it might open new paths on the cardioprotective effects of vaccination.


ADE; Covid-19; SARS-CoV-2; Th17; vaccine

Full Text: PDF HTML


  • There are currently no refbacks.

Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.